Late Friday afternoon, January 22, 2010, the Food and Drug Administration (FDA) announced that they approved AMPYRA™ (dalfampridine, formerly known as fampridine-SR) as a treatment to improve walking in multiple sclerosis patients. Developed by Acorda Therapeutics in partnership with Elan Corp, AMPYRA™ is a proprietary slow-release formulation of the compounded drug 4-aminopyridine (4-AP).
Although the name AMPYRA™ only hit the internet on Friday, the drug and its predecessor...
I have noticed a trend in our monthly MS Town Hall Meetings: Despite (or maybe because of) the potential risks involved with the newer... Read more »
If so, then Acorda Therapeutics, Inc. would like you to know that on January 30, 2009, they submitted a New Drug Application (NDA) to the... Read more »
In the summer of 2005, I met several MS patients who were undergoing Solumedrol treatments. I was in the infusion clinic for a release as... Read more »
The latest from Neurology on MS. Takin’ It to the Streets- by the Doobie Brothers/Michael McDonald You don’t know me but I'm your... Read more »
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
